NCT06212089View on ClinicalTrials.gov

Phase II Clinical Study of TR-012001 in Japanese Patients With Parkinson's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 28, 2023

Primary Completion Date

April 26, 2024

Study Completion Date

May 30, 2024

Conditions
Parkinson Disease
Interventions
DRUG

TR-012001

A single dose of TR-012001 will be administered.

OTHER

Placebo

A single dose of placebo will be administered.

Trial Locations (1)

799-1592

Saiseikai Imabari Hospital, Imabari

All Listed Sponsors
lead

SNLD, Ltd.

INDUSTRY

NCT06212089 - Phase II Clinical Study of TR-012001 in Japanese Patients With Parkinson's Disease | Biotech Hunter | Biotech Hunter